Improved anti-tumor activity and safety profile of a paclitaxel-loaded glycyrrhetinic acid-graft-hyaluronic acid conjugate as a synergistically targeted drug delivery system

Chinese Journal of Natural Medicines

Volumn 13, Issue 12, 2015, Pages 915-924

  Zhang, Li ^a,b   Zhou, Jian Ping ^a   Yao, Jing ^a  

^a China Pharmaceutical University   (China)

^b Department of Pharmacy   (China)

Author keywords

Antitumor activity; Conjugate; Glycyrrhetinic acid; Hyaluronic acid; Synergistically targeted delivery

Indexed keywords

GLYCYRRHETINIC ACID; HYALURONIC ACID; NANOCARRIER; PACLITAXEL; ANTINEOPLASTIC AGENT; DRUG CARRIER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; HEPG2 CELL LINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; MOUSE; NONHUMAN; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT CHANGE; ANIMAL; CHEMISTRY; DEVICES; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; HEP-G2 CELL LINE; HUMAN; MALE; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; FEMALE; GLYCYRRHETINIC ACID; HEP G2 CELLS; HUMANS; HYALURONIC ACID; MALE; MICE; PACLITAXEL;

EID: 84951070134     PISSN: 20956975     EISSN: 18755364     Source Type: Journal    
DOI: 10.1016/S1875-5364(15)30097-2     Document Type: Article

References (35)

1. Micha JP, Sassoon AF, Wong H, et al. Prolonged remission of recurrent cervical carcinoma following paclitaxel and carboplatin chemotherapy with paclitaxel maintenance chemotherapy [J]. Anticancer Drugs 2015, 26(7):793-796.
2. Bao QY, Zhang N, Geng DD, et al. The enhanced longevity and liver targetability of Paclitaxel by hybrid liposomes encapsulating Paclitaxel-conjugated gold nanoparticles [J]. Int J Phramceut 2014, 477(1-2):408-415.
3. Jiang L, Li L, He X, et al. Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response [J]. Biomaterials 2015, 52:126-139.
4. Rivkin I, Cohen K, Koffler J, et al. Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors [J]. Biomaterials 2010, 31(27):7106-7114.
5. Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation [J]. Eur J Cancer 2001, 37(13):1590-1598.
6. Tomaru A, Takeda-Morishita M, Maeda K, et al. Effects of Cremophor EL on the absorption of orally administered saquinavir and fexofenadine in healthy subjects [J]. Drug Metab Pharmacokinet 2015, 30(3):221-226.
7. Danhier FL, Feron O, Préat V To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery [J]. J Control Release 2010, 148(2):135-146.
8. Yao J, Fan Y, Du R, et al. Amphoteric hyaluronic acid derivative for targeting gene delivery [J]. Biomaterials 2010, 31(35):9357-9365.
9. Liang DS, Su HT, Liu YJ, et al. Tumor-specific penetrating peptides-functionalized hyaluronic acid-d-α-tocopheryl succinate based nanoparticles for multi-task delivery to invasive cancers [J]. Biomaterials 2015, 71:11-23.
10. Ghosh SC, Alpay SN, Klostergaard J CD44: a validated target for improved delivery of cancer therapeutics [J]. Expert Opin Ther Targets 2012, 16(7):635-650.
11. Negishi M, Irie A, Nagata N, et al. Specific binding of glycyrrhetinic acid to the rat liver membrane [J]. Biochim Biophys Acta 1991, 1066(1):77-82.
12. Rohilla R, Garq T, Bariwal J, et al. Development, optimization and characterization of glycyrrhetinic acid-chitosan nanoparticles of atorvastatin for liver targeting [J]. Drug Deliv 2015, 14:1-8.
13. Zhang L, Yao J, Zhou JP, et al. Glycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs [J]. Int J Phramceut 2013, 441(1-2):654-664.
14. Hou L, Fan Y, Yao J, et al. Low molecular weight heparin-all-trans-retinoid acid conjugate as a drug carrier for combination cancer chemotherapy of paclitaxel and alltrans-retinoid acid [J]. Carbohydr Polym 2011, 86:1157-1166.
15. Yao J, Zhang L, Zhou JP, et al. Efficient simultaneous tumor targeting delivery of all-trans retinoid acid and Paclitaxel based on hyaluronic acid-based multifunctional nanocarrier [J]. Mol Pharm 2013, 10(3):1080-1091.
16. Zhang L, Zhou JP, Yao J Preparation and properties of pactlitaxel-loaded glycyrrhetinic acid-modified hyaluronic acid nanoparticles [J]. J Chn Pharma Univ 2012, 43(3):226-230.
17. Cho HJ, Yoon HY, Koo H, et al. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel [J]. Biomaterials 2011, 32:7181-7190.
18. Yoon HY, Kim HR, Saravanakumar G, et al. Bioreducible hyaluronic acid conjugates as siRNA carrier for tumor targeting [J]. J Control Release 2013, 172(3):653-661.
19. Zhang LS, Greyner HJ, Mummert ME, et al. Development of a hyaluronan bioconjugate for the topical treatment of melanoma [J]. J Dermatol Sci 2009, 55(1):56-59.
20. Wang W, Ruan YX, Xing XB, et al. Curcumin induced nanoscale CD44 molecular redistribution and antigen-antibody interaction on HepG2 cell surface [J]. Anal Chim Acta 2011, 697(1-2):83-89.
21. Zhang XJ, Liu YP, Hou KZ, et al. Molecular mechanism of A375 cell apoptosis induced by paclitaxel [J]. Chin J Cancer Prev Treat 2005, 22(12):1710-1715.
22. Jordan MA, Toso RJ, Thrower D, et al. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations [J]. Proc Natl Acad Sci USA 1993, 90(20):9552-9556.
23. Donaldson KL, Goolsby GL, Kiener PA, et al. Activation of p34cdc2 coincident with taxol-induced apoptosis [J]. Cell Growth Differ 1994, 5(10):1041-1050.
24. Coradini D, Zorzet S, Rossin R, et al. Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But [J]. Clin Cancer Res 2004, 10:4822-4830.
25. Acharya S, Sahoo SK Sustained targeting of Bcre-Abl + leukemia cells by synergistic action of dual drug loaded nanoparticles and its implication for leukemia therapy [J]. Biomaterials 2011, 32(24):5643-5662.
26. Kaufmann SH, Hengartner MO Programmed cell death: alive and well in the new millennium [J]. Trends Cell Biol 2001, 11(12):526-534.
27. Robert FP, Robert K Polymeric nanoparticles and microparticles for the delivery of peptides, biologics, and soluble therapeutics [J]. J Control Release 2015, 219:519-535.
28. Zhong YN, Zhang J, Cheng R, et al. Reversibly crosslinked hyaluronic acid nanoparticles for actie targeting and intelligent delivery of doxorubicin to drug resistant CD44 + human breast tumor xenografts [J]. J Control Release 2015, 205:144-154.
29. Lammers T, Kiessling F, Hennink WE, Storm G Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress [J]. J Control Release 2012, 161(2):175-187.
30. Thomas RG, Moon MJ, Lee H, et al. Hyaluronic acid conjugated superparamagnetic iron oxide nanoparticle for cancer diagnosis and hyperthermia therapy [J]. Carbohydr Polym 2015, 131:439-446.
31. He ZY, Zheng X, Wu XH, et al. Development of glycyrrhetinic acid-mofidied stealth cationic liposomes for gene delivery [J]. Int J Phramceut 2010, 397:147-154.
32. Tian Q, Zhang CN, Wang XH, et al. Glycyrrhetinic acid-modifiedchitosan/poly (ethylene glycol) nanoparticles for liver-targeted delivery [J]. Biomaterials 2010, 31:4748-4756.
33. Wei H, Wei W, Ping W, et al. Glycyrrhetinic acid-modified poly(ethylene glycol)-b-poly(γ-benzyl L-glutamate) micelles for liver targeting therapy [J]. Acta Biomater 2010, 6:3927-3935.
34. Quader S, Cabral H, Mochida Y, et al. Selective intracellular delivery of proteasome inhibitors through pH-sensitive polymeric micelles directed to efficient antitumor therapy [J]. J Control Release 2014, 188:67-77.
35. Pan D, She W, Guo C, et al. PEGylated dendritic diaminocyclohexyl-platinum (II) conjugates as pH-responsive drug delivery vehicles with enhanced tumor accumulation and antitumor efficacy [J]. Biomaterials 2014, 35(38):10080-10092.